Fluxion Biosciences Inc.

Fluxion Biosciences Inc., doing business as Fluxion, is a manufacturer of automated patch clamp, cellular analysis, and liquid biopsy systems. The company provides specialized biofluxion equipment, upgrades, cell lines, and microfluidic devices to various federal agencies through contracts and grants. Registered to receive federal awards since December 7, 2005, Fluxion is classified as a for-profit organization and manufacturer of goods. The company's expertise lies in developing and supplying advanced laboratory equipment and systems for biomedical research and clinical applications.

Through federal contract awards, Fluxion has primarily supplied specialized biofluxion equipment and related services to civilian agencies. The Department of Veterans Affairs Veterans Health Administration has awarded multiple delivery orders to Fluxion for the procurement of bio fluxion equipment, with contract values of $34,150 each and performance periods extending to January 31, 2028. These orders support the VA's healthcare programs for veterans in the Houston, Texas area. The Centers for Disease Control and Prevention (CDC) has also contracted Fluxion for various projects, including a $110,000 purchase order to upgrade an Ionflux Mercury 16 system to a 96- to 386-well capability, and a $126,311.80 order for a recombinant cell line. Additionally, the National Cancer Institute awarded Fluxion a $53,803 purchase order for a Fluxion Bioflux 200 microfluidic device system to support cancer research. These contracts demonstrate Fluxion's capability to provide cutting-edge laboratory equipment and customized solutions for federal research and healthcare initiatives.

Fluxion has also received federal grant awards for research and development projects. The National Heart Lung and Blood Institute awarded Fluxion a project grant (R43HL150946) for the development of a "Platelet Production in a Pulmonary-Based Microfluidic Reactor." This grant, awarded on June 1, 2020, had a completion date of November 30, 2021. Another project grant (R43HD100217) was awarded by the National Institute of Child Health and Human Development on September 16, 2019, for "A Novel NIPT Assay Based on Single Cell Sequencing," with a completion date of March 31, 2020. These grants highlight Fluxion's involvement in innovative research projects related to hematology and prenatal testing, leveraging their expertise in microfluidic and cellular analysis technologies.

Fluxion holds a federal contract Indefinite Delivery Vehicle (IDV) awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 17. This single-award IDV, with ID 36C25623D0035, was established on February 1, 2023, with a ceiling value of $200,000 and an ultimate completion date of January 31, 2028. The IDV is for the procurement of bio fluxion equipment, supporting the VA's healthcare programs in the Houston, Texas area. An initial task order worth $34,150 was issued under this IDV for equipment with the same performance period. This IDV demonstrates the ongoing relationship between Fluxion and the VA, providing a streamlined procurement process for specialized bioscience equipment to support veteran healthcare services.